Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Culpepper Peter R and Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Peter R. Culpepper 3,474,998 0 3,474,998 0 3,474,998 1.4%

Page 1 of 4 – SEC Filing



Washington, D.C. 20549




Under the Securities Exchange Act of 1934

(Amendment No. 3)



Biopharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)


(CUSIP Number)

with copies to:

Peter R. Culpepper

P.O. Box 32429

TN 37930

(865) 604-0657

David W. Bernstein, Esq.

Goodwin Procter LLP

New York Times Building

620 Eighth Avenue

New York, NY 10018


(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

March 30, 2017

(Date of Event Which Requires Filing of this Statement)



If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box  ☐.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for
other parties to whom copies are to be sent.

(Continued on following pages)

Follow Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT)